General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Kwality Pharmaceuticals reported revenue of ₹162.35 crore for the three months to June 2026. Operating profit came in at ₹41.02 crore and profit after tax at ₹25.62 crore. The same quarter a year earlier brought revenue of ₹111.48 crore. Operating profit then was ₹24.17 crore, and profit after tax ₹11.93 crore. Revenue rose 45.6% over the year and operating profit 69.7%. Profit after tax rose 114.8%. Against the March 2026 quarter, revenue rose 3.3% and profit after tax 1.3%. Next to the yearly column, the sequential one looks like a short nap.
The quarter was busier elsewhere. Thirteen bioequivalence studies were completed, the tests that show a copy behaves like the original medicine. Seven came from the General unit and two from Beta Lactam. Oncology accounted for the other four. The programme they sit inside covers 40 molecules. More than fifteen new product registrations landed, across Malaysia, Algeria, Peru and Mexico. Pembrolizumab received approval to begin pre-clinical batches. Erythropoietin moved to the clinical trial stage.
In May 2026 ICRA, a credit-rating agency, upgraded the long-term rating to [ICRA]BBB+ (Stable) from [ICRA]B+ (Stable). The same action removed the company from ICRA’s Issuer Not Cooperating category. It is a five-notch move, and part of earning it was answering the phone again.
Management has raised guidance for the year to March 2027. It now points to revenue above ₹700 crore and profit after tax above ₹109 crore. The EBITDA guide — profit before interest, tax and depreciation — is ₹189 crore to 196 crore or more. The base beneath those figures is revenue of ₹503.08 crore in the year to March 2026. Net profit that year was ₹67.35 crore.
2. Introduction
Kwality Pharmaceuticals was incorporated in Amritsar in 1983. It has been making medicine for longer than most of its 1,750-odd employees have been alive. Per ICRA, a credit-rating agency, it began as a private limited company promoted by Mr Ramesh Arora. ICRA records a reconstitution as a closely held public limited company in 1993. The shares listed on the BSE SME platform in July 2016 and moved to the BSE main board in June 2022. Four decades of pharmaceutical manufacturing came before the ticker.
The years since read as a steady accumulation of certificates. Per the company’s presentation, beta lactam and biological units were established around 2020 to 2022. EU GMP approval for injectables followed, EU GMP being the European Union’s factory quality standard. Then came PIC/S GMP approvals, an international scheme under which regulators recognise each other’s inspections. SFDA approval covered the General and Beta Lactam units. The most recent year brought EU-GMP approval for the general and beta lactam plants. Four of the five manufacturing plants now hold EU-GMP approval. Cumulative regulatory filings have gone from 75 in the year to March 2023 to more than 700. Of those, 200 were filed in the year to March 2026 alone.
Revenue was ₹251 crore in the year to March 2023 and ₹307 crore the year after. It reached ₹370 crore, then ₹503 crore in the year to March 2026. Net profit over the same four years began at ₹19.37 crore and then ₹23.80 crore. It was ₹39.85 crore, then ₹67.35 crore in the most recent year.
The record also holds a harder entry. In October 2023 the company disclosed a fire accident at its Amritsar plant involving employee fatalities. It filed an update on the resumption of operations in the same month.
The recent filings are routine. An investor knowledge session was held on 10 August 2026. The earnings call transcript was filed on 12 August, alongside the notice of the 43rd Annual General Meeting. A company that places its own newspaper advertisements has been doing this a while. The June quarter results were published in the newspapers on 13 August.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
The company makes medicines in almost every physical shape a medicine takes. It states a portfolio of more than 1,000 formulations across more than 25 therapeutic areas. Older Screener commentary puts the count above 3,000, and both figures sit in the record.
In the year to March 2026, injectables were 48% of revenue and tablets 38%. Capsules contributed 5%, and liquid externals and oral liquids 3%. Creams and ointments were 2%. Dry syrups, ophthalmics, sachets and suppositories came in at 1% each. Someone in Amritsar runs a suppository line worth one percent of a ₹503 crore business, and it meets EU GMP standards anyway.
Five units sit across two campuses. Campus 1 in Amritsar holds Unit 1 (General Formulations), Unit 2 (Beta Lactam) and Unit 5 (Biologics). Campus 2 in Himachal Pradesh holds Unit 3 (Oncology) and Unit 4 (Cephalosporins). The stated annual capacities stop meaning much after a while. The beta lactam unit alone lists 3,000 million tablets and 1,500 million capsules. Unit 1 lists 200 million ampoules and 200 million vials. There are also 40 million dental cartridges, dentists having earned a line of their own.
Manufacturing revenue in the year to March 2026 came 60% from Unit 1 and 26% from Unit 3. Unit 2 supplied 10% and Unit 4 the remaining 4%.
The commercial model is 90% out-licensing and supply, with 10% CDMO work, which means making products
